Verrica Pharmaceuticals Inc. (VRCA) earnings
VRCA earnings moved a median of -3.60% by the close. Quarterly and annual VRCA reports and results, each read against the price at its own news timestamp. Back to the VRCA overview →
26 measured VRCA earnings events.
Where these VRCA earnings landedvs 26 measured VRCA earnings reactions
| Middle 50% of VRCA earnings reactions | -9.74% to +6.66% |
|---|---|
| Median reaction (to close) | -3.60% |
| Measured reactions | 26 |
Point-in-time · zero look-ahead
Half of the 26 VRCA earnings events with a measured close landed between -9.74% and +6.66%; 35% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Verrica Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | +1.41% | -4.33% | |
| Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results | Press release | +1.41% | -4.33% | |
| Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 | Press release | +0.00% | +1.74% | |
| Form 10-Q Verrica Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | +0.51% | +6.66% | |
| Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results | Press release | +0.51% | +6.66% | |
| Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026 | Press release | +0.00% | +11.35% | |
| Form 10-K Verrica Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | +14.26% | +23.96% | |
| Form 10-Q Verrica Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | +0.00% | -2.87% | |
| Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results | Press release | +0.00% | -2.87% | |
| Form 10-Q Verrica Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | -2.84% | -6.53% | |
| Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results | Press release | -2.84% | -6.53% | |
| Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025 | Press release | +0.00% | +9.00% | |
| Form 10-Q Verrica Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | -8.86% | -2.67% | |
| Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025 | Press release | +7.12% | -8.75% | |
| Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025 | Press release | -8.51% | +21.75% | |
| Form 10-K Verrica Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | -3.17% | -4.71% | |
| Form 10-Q Verrica Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | -3.80% | -14.25% | |
| Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition | Press release | -3.80% | -14.25% | |
| Form 10-Q Verrica Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | -10.44% | -40.80% | |
| Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results | Press release | -10.44% | -40.80% | |
| Form 10-Q Verrica Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | -1.22% | +16.30% | |
| Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results | Press release | -1.22% | +16.30% | |
| Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024 | Press release | +0.79% | -0.13% | |
| Form 10-K Verrica Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | -1.88% | -10.07% | |
| Form 10-Q Verrica Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | -1.39% | -10.83% | |
| Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results | Press release | -1.39% | -10.83% |
Keep exploring
More VRCA: analyst actions → · SEC filings → · VRCA overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Achieve Life Sciences, Inc. - Common Shares (ACHV) | 269 | -0.54% | 42% |
| CorMedix Inc. (CRMD) | 269 | -0.42% | 39% |
| CONMED Corporation (CNMD) | 268 | -0.11% | 47% |
| Codexis, Inc. (CDXS) | 267 | 0.00% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.